Founded in 1983, Emcure Pharmaceuticals manufactures and globally markets a wide variety of pharmaceutical products. It has filed its draft red herring prospectus (DRHP) with the Securities Exchange Board of India (SEBI) to raise funds through an IPO (initial public offering). The Pune-based company is the 12th largest pharmaceutical company in India. As per the CRISIL report FY21, Emcure Pharmaceutical Limited is a leader (as per sales numbers) in three therapeutic areas: gynaecology, blood-related and HIV antivirals. The company is acknowledged for its diverse product portfolio, including injectables, orals and biologics. The company also has a Messenger RNA (mRNA) platform, which is currently developing a COVID-19 vaccine. With a globally diversified empire, including 19 subsidiaries, 500 scientists and 11,000 employees, the pharma giant IPO aims to encash the growing potential of the pharmaceutical sector.

For year/ period ended ( in Cr.)

• Repaying, either whole or part of the borrowings, which stood at Rs. 1,712 crore as of 31 March 2021.
• General corporate purposes

The company has been profitable for the last three years: FY21, FY20 and FY19. Between FY19 and FY21, the net profit rose by a CAGR of 41%. The total revenue was up 12.5% during the same period. With solid financials and interesting future product launches, Emcure Pharma IPO is a much-awaited one. However, with five other pharmaceutical companies launching their IPO this year, the competition in the stock market is likely to intensify.